Blurbs

Analysts Conflicted on These Healthcare Names: Orthofix (OFIX) and Immunovant (IMVT)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Orthofix (OFIXResearch Report) and Immunovant (IMVTResearch Report).

Orthofix (OFIX)

JMP Securities analyst David Turkaly reiterated a Hold rating on Orthofix today. The company’s shares closed last Friday at $15.00, close to its 52-week low of $13.76.

According to TipRanks.com, Turkaly is a 2-star analyst with an average return of 0.2% and a 41.0% success rate. Turkaly covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Integra Lifesciences, and OrthoPediatrics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Orthofix with a $28.00 average price target.

See Insiders’ Hot Stocks on TipRanks >>

Immunovant (IMVT)

In a report released today, Mike Kratky from SVB Securities maintained a Buy rating on Immunovant, with a price target of $14.00. The company’s shares closed last Friday at $12.05, close to its 52-week high of $12.42.

According to TipRanks.com, Kratky is a 3-star analyst with an average return of 9.0% and a 62.5% success rate. Kratky covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, Pliant Therapeutics, and Kymera Therapeutics.

Immunovant has an analyst consensus of Moderate Buy, with a price target consensus of $10.60.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on OFIX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More